Clinicopathological spectrum of solitary Plasmacytoma

A single center experience from coastal India

Sridevi Hanaganahalli Basavaiah, Flora D. Lobo, Cheryl Sarah Philipose, Pooja K. Suresh, Saraswathy Sreeram, Hema Kini, Kausalya K. Sahu, Krishna Prasad

Research output: Contribution to journalArticle

Abstract

Background: Plasma cell disorders are a rare group of hematological malignancies that accounts for 10% of all hematological neoplasms. Solitary plasmacytomas are rarer entities accounting for less than 5% of all the plasma cell dyscrasias. They encompass three subtypes - Solitary Plasmacytoma of Bone (SPB) and Solitary Extramedullary Plasmacytoma (SEP) and multiple solitary plasmacytomas (MSP). In this study, we discuss the clinical, histopathological and immunohistochemical characteristics of solitary plasmacytomas. Methods: A 13 year retrospective analysis of solitary plasmacytomas was performed from a single tertiary care center. Bone marrow evaluation was done concurrently at the time of diagnosis to rule out the presence of multiple myeloma. Results: A total of 29 cases fulfilled the diagnostic criteria for SP during the study period. SPB accounted for 55.2%, SEP for 44.4% and MSP for 3.4% of the cases. The most common sites involved were the paranasal sinuses and vertebrae. Other infrequent sites included lymph node, tonsil and lungs. The mean age of presentation of SPB was a decade later than SEP. A male preponderance was observed in both subtypes. Conclusion: Solitary plasmacytoma is a rare entity, the diagnosis of which requires a systematic approach. There is limited data available in the literature on the clinico-pathological characteristics of SP from India.

Original languageEnglish
Article number801
JournalBMC Cancer
Volume19
Issue number1
DOIs
Publication statusPublished - 14-08-2019

Fingerprint

Plasmacytoma
India
Hematologic Neoplasms
Bone and Bones
Paraproteinemias
Paranasal Sinuses
Palatine Tonsil
Plasma Cells
Multiple Myeloma
Tertiary Care Centers
Spine
Lymph Nodes
Bone Marrow

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Basavaiah, Sridevi Hanaganahalli ; Lobo, Flora D. ; Philipose, Cheryl Sarah ; Suresh, Pooja K. ; Sreeram, Saraswathy ; Kini, Hema ; Sahu, Kausalya K. ; Prasad, Krishna. / Clinicopathological spectrum of solitary Plasmacytoma : A single center experience from coastal India. In: BMC Cancer. 2019 ; Vol. 19, No. 1.
@article{2695f9ade2d1449db0817b05e6463cf9,
title = "Clinicopathological spectrum of solitary Plasmacytoma: A single center experience from coastal India",
abstract = "Background: Plasma cell disorders are a rare group of hematological malignancies that accounts for 10{\%} of all hematological neoplasms. Solitary plasmacytomas are rarer entities accounting for less than 5{\%} of all the plasma cell dyscrasias. They encompass three subtypes - Solitary Plasmacytoma of Bone (SPB) and Solitary Extramedullary Plasmacytoma (SEP) and multiple solitary plasmacytomas (MSP). In this study, we discuss the clinical, histopathological and immunohistochemical characteristics of solitary plasmacytomas. Methods: A 13 year retrospective analysis of solitary plasmacytomas was performed from a single tertiary care center. Bone marrow evaluation was done concurrently at the time of diagnosis to rule out the presence of multiple myeloma. Results: A total of 29 cases fulfilled the diagnostic criteria for SP during the study period. SPB accounted for 55.2{\%}, SEP for 44.4{\%} and MSP for 3.4{\%} of the cases. The most common sites involved were the paranasal sinuses and vertebrae. Other infrequent sites included lymph node, tonsil and lungs. The mean age of presentation of SPB was a decade later than SEP. A male preponderance was observed in both subtypes. Conclusion: Solitary plasmacytoma is a rare entity, the diagnosis of which requires a systematic approach. There is limited data available in the literature on the clinico-pathological characteristics of SP from India.",
author = "Basavaiah, {Sridevi Hanaganahalli} and Lobo, {Flora D.} and Philipose, {Cheryl Sarah} and Suresh, {Pooja K.} and Saraswathy Sreeram and Hema Kini and Sahu, {Kausalya K.} and Krishna Prasad",
year = "2019",
month = "8",
day = "14",
doi = "10.1186/s12885-019-5976-7",
language = "English",
volume = "19",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Clinicopathological spectrum of solitary Plasmacytoma : A single center experience from coastal India. / Basavaiah, Sridevi Hanaganahalli; Lobo, Flora D.; Philipose, Cheryl Sarah; Suresh, Pooja K.; Sreeram, Saraswathy; Kini, Hema; Sahu, Kausalya K.; Prasad, Krishna.

In: BMC Cancer, Vol. 19, No. 1, 801, 14.08.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinicopathological spectrum of solitary Plasmacytoma

T2 - A single center experience from coastal India

AU - Basavaiah, Sridevi Hanaganahalli

AU - Lobo, Flora D.

AU - Philipose, Cheryl Sarah

AU - Suresh, Pooja K.

AU - Sreeram, Saraswathy

AU - Kini, Hema

AU - Sahu, Kausalya K.

AU - Prasad, Krishna

PY - 2019/8/14

Y1 - 2019/8/14

N2 - Background: Plasma cell disorders are a rare group of hematological malignancies that accounts for 10% of all hematological neoplasms. Solitary plasmacytomas are rarer entities accounting for less than 5% of all the plasma cell dyscrasias. They encompass three subtypes - Solitary Plasmacytoma of Bone (SPB) and Solitary Extramedullary Plasmacytoma (SEP) and multiple solitary plasmacytomas (MSP). In this study, we discuss the clinical, histopathological and immunohistochemical characteristics of solitary plasmacytomas. Methods: A 13 year retrospective analysis of solitary plasmacytomas was performed from a single tertiary care center. Bone marrow evaluation was done concurrently at the time of diagnosis to rule out the presence of multiple myeloma. Results: A total of 29 cases fulfilled the diagnostic criteria for SP during the study period. SPB accounted for 55.2%, SEP for 44.4% and MSP for 3.4% of the cases. The most common sites involved were the paranasal sinuses and vertebrae. Other infrequent sites included lymph node, tonsil and lungs. The mean age of presentation of SPB was a decade later than SEP. A male preponderance was observed in both subtypes. Conclusion: Solitary plasmacytoma is a rare entity, the diagnosis of which requires a systematic approach. There is limited data available in the literature on the clinico-pathological characteristics of SP from India.

AB - Background: Plasma cell disorders are a rare group of hematological malignancies that accounts for 10% of all hematological neoplasms. Solitary plasmacytomas are rarer entities accounting for less than 5% of all the plasma cell dyscrasias. They encompass three subtypes - Solitary Plasmacytoma of Bone (SPB) and Solitary Extramedullary Plasmacytoma (SEP) and multiple solitary plasmacytomas (MSP). In this study, we discuss the clinical, histopathological and immunohistochemical characteristics of solitary plasmacytomas. Methods: A 13 year retrospective analysis of solitary plasmacytomas was performed from a single tertiary care center. Bone marrow evaluation was done concurrently at the time of diagnosis to rule out the presence of multiple myeloma. Results: A total of 29 cases fulfilled the diagnostic criteria for SP during the study period. SPB accounted for 55.2%, SEP for 44.4% and MSP for 3.4% of the cases. The most common sites involved were the paranasal sinuses and vertebrae. Other infrequent sites included lymph node, tonsil and lungs. The mean age of presentation of SPB was a decade later than SEP. A male preponderance was observed in both subtypes. Conclusion: Solitary plasmacytoma is a rare entity, the diagnosis of which requires a systematic approach. There is limited data available in the literature on the clinico-pathological characteristics of SP from India.

UR - http://www.scopus.com/inward/record.url?scp=85070997564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070997564&partnerID=8YFLogxK

U2 - 10.1186/s12885-019-5976-7

DO - 10.1186/s12885-019-5976-7

M3 - Article

VL - 19

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 801

ER -